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Abstract Inducible nitric oxide synthase (iNOS) is modulated
at the transcriptional level. Overexpression of this protein may
result in high levels of nitric oxide leading to tissue damage and
immunosuppression. In order to reduce the pathological effects of
NO overproduction many efforts have been devoted to the
identification of specific inhibitors of iNOS. The discovery of
peptide nucleic acids (PNA), a novel class of molecules able to
selectively interact with nucleic acids, prompted us to attempt a
new way for the regulation of NO production. Here we describe
the synthesis, characterization and in vitro effects of a PNA
molecule bearing a homopyrimidine sequence complementary to
the 5P coding region of murine iNOS mRNA. This PNA shows
specific interactions with iNOS mRNA in RNase protection
assays and is able to block the synthesis of iNOS protein
selectively in a rabbit reticulocyte lysate system. These results
strengthen the view of a possible pharmacological application of
PNA as a compound able to interfere with a specific enzymatic
activity even at low concentrations.
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1. Introduction
In recent years nitric oxide (NO) has been increasingly dem-
onstrated to play a fundamental role in cellular functions and
in intercellular communications, while its concentration
proved to be critical both in physiological and in pathological
events [1,2]. In particular, e¡ects of NO in the regulation of
vascular homeostasis, as well as its involvement in neurotrans-
mission and in the defense against infectious agents, have been
demonstrated [2^4]. However, it has also been reported that
imbalances in NO intracellular levels may be responsible for
various pathological alterations, such as septic shock, hyper-
tension, stroke and neurodegenerative diseases. [5^7].
This signal metabolite is synthesized by three distinct iso-
forms of NO synthase (NOS) [2,8,9] : the brain and endothe-
lial enzymes are constitutively expressed and their enzymatic
activity is calcium-dependent; in contrast, the inducible NOS
(iNOS) is regulated at the transcriptional level by endotoxin
and cytokines and is not dependent on calcium concentrations
in the physiological range. This latter isoenzyme is responsible
for the high production of NO by macrophages in response to
various in£ammatory stimuli [4]. In these circumstances, NO
mediates antimicrobial and antitumor activities of the immune
system [4], but, under certain conditions, high levels of NO
cause tissue damage and autoimmune diseases [1,2]. These
opposite e¡ects suggest that iNOS is under particularly re¢ned
mechanisms of regulation and the search for speci¢c modula-
tors of its enzyme activity is actively pursued.
Most of the currently used pharmacological inhibitors of
iNOS may also a¡ect the other two isoforms of NOS and
to some degree interfere with unrelated metabolic pathways
of cells [2,4]. Therefore, an antisense strategy might result in a
more selective pharmacological control of iNOS. Natural oli-
gonucleotides are potentially useful tools although their fast in
vivo degradation suggests the use of nuclease-resistant ana-
logues. Peptide nucleic acids (PNA) [10] are structural homo-
logues of RNA and DNA in which the entire deoxyribose
phosphate moiety is replaced by an uncharged pseudo-peptide
backbone consisting of N-(2-aminoethyl)glycine units linked
to the purine and pyrimidine bases of natural nucleic acids
(Scheme 1). This potent DNA mimic was found to form very
stable complexes with speci¢c DNA or RNA sequences [10^
13] and to be resistant to enzymatic degradation in biological
£uids and tissues [14]. Because of these very promising proper-
ties PNA can be considered new potential drugs able to inter-
fere with gene expression at the transcriptional or translation-
al level [15,16].
In this study we have explored the ability of a homopyr-
imidine PNA probe to bind speci¢cally murine iNOS mRNA
and consequently to inhibit its translation. RNase protection
assays were performed to verify the speci¢c hybridization of
PNA to iNOS mRNA, while the inhibitory e¡ect of PNA on
iNOS expression was ascertained in a rabbit reticulocyte ly-
sate system.
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2. Materials and methods
2.1. Synthesis of PNAs
PNAs were manually synthesized through the standard method of
solid phase peptide synthesis using the Boc strategy [17,18] with minor
modi¢cations as described in [19].
PNAs sequences were as follows: PNA1 Gly-Lys-CTTTCT-
CCTTTTCCNH2, complementary to the homopurine region 238^
251 of the iNOS mouse cDNA (accession number M84373), and
PNA2 (scrambled) Gly-Lys-CTTTTTCCCTCTTCNH2, used as con-
trol.
The products were analyzed by coupling the RP-HPLC to an ES
mass spectrometer using the same conditions described in a previous
work [19].
2.2. cDNA of iNOS
iNOS cDNA (inserted in pUC19 vector) was kindly provided by
Dr. Luigi Varesio (Istituto Gaslini, Genoa, Italy). cDNA was ampli-
¢ed under the following PCR conditions: 94‡C for 10 s, 68‡C for
3 min for 20 cycles; the 100 Wl reaction volume contained Thermo
Bu¡er (Promega, Madison, WI, USA), 0.2 mM dNTP (Pharmacia,
Uppsala, Sweden), 10 pmol primers, 1 mM MgCl2 and 2.5 U Taq
polymerase (Promega). Oligonucleotide primers were obtained from
TIBMOLBIOL, Genoa, Italy and were: 5P-AATTAGATCTCA-
CCTTGGTGAAGGGACTGAGC-3P (sense) and 5P-AATTAA-
GCTTTGCAGCTAAGTATTAGAGCGGCG-3P (antisense), corre-
sponding to regions 44^65 and 3940^3962 of mouse iNOS. The pri-
mers also contained speci¢c sequences for the BglII (sense) or HindIII
(antisense) restriction enzymes. The product of ampli¢cation of 3918
bp contained the complete coding region.
The puri¢ed ampli¢cation product was digested with BglII and
HindIII restriction enzymes (Amersham, Milan, Italy) and ligated
into BamHI and HindIII sites of pSP65 plasmid (Promega), which
contains SP6 RNA polymerase promoter, using standard protocols
[20].
2.3. SP6 RNA polymerase transcription
pSP65 plasmid containing iNOS cDNA was linearized by digestion
with HindIII [20]. Radiolabelled iNOS mRNA transcription, to be
used in the RNase protection assay, was obtained in a 20 Wl sample
containing 1USP6 bu¡er (Amersham), 2 Wg of template, 30 U of SP6
RNA Polymerase (Amersham), 10 mM DTT (Sigma, St. Louis, MO,
USA), 0.5 mM ATP-CTP-UTP mix (Pharmacia, Uppsala, Sweden),
12.5 WM GTP (Pharmacia), 60 WCi [K-32P]GTP (3000 Ci/mmol, Amer-
sham), 20 U RNase inhibitor (Amersham), 0.01% BSA (Amersham).
The mixture was incubated for 2 h at 40‡C, then 20 U of RNase-free
DNase (Boehringer Mannheim Italia, Monza, Italy) was added and
the solution was maintained at 37‡C for 20 min. Finally, radiolabelled
iNOS mRNA was extracted with PCA, ethanol-precipitated [20] and
resuspended in 20 Wl RNase-free water. The solution was heated at
65‡C for 10 min to denature mRNA.
In order to obtain the non-radiolabelled iNOS mRNA to be used in
the rabbit reticulocyte lysate experiments 11 Wg of cDNA template
was incubated with 150 U SP6 RNA polymerase as described above,
using 0.5 mM dNTP.
2.4. RNase protection
Samples (20 Wl) containing iNOS radiolabelled mRNA (500 000
cpm), 0.3 M NaCl, 10 mM Tris pH 7.4, 4 mM EDTA, 0.02%
tRNA (all from Sigma) and 1 WM PNA1 or 1 WM PNA2, were
incubated at 42‡C for 30 min, then 20 U RNase T1, 2.5 Wg RNase
A and 1.5 Wg BSA were added and the solution was incubated for 1 h
at 37‡C [21]. RNA fragments were analyzed by 7 M urea/20% poly-
acrylamide gel electrophoresis followed by autoradiography as de-
scribed [20].
2.5. Cell cultures
The mouse macrophage cell line RAW 264.7 was obtained from the
American Type Culture Collection (Rockville, MD, USA) and was
cultured in DMEM containing 4 mM glutamine and supplemented
with 10% FCS [22]. Cell stimulation was performed by adding 10 U/
ml mouse recombinant IFNQ (Sigma) and 50 ng/ml LPS (Sigma).
2.6. Puri¢cation of RAW 264.7 poly(A)+
Total RNA was puri¢ed from unstimulated RAW 264.7 and cells
stimulated with LPS and IFNQ for 6 h using described protocols
[23,24]. Poly(A) was obtained from total RNA using oligo(dT)-cel-
lulose type 77F and following the supplier’s protocol (Pharmacia Bio-
tech, Cologno Monzese, MI, Italy).
2.7. Rabbit reticulocyte lysate system
Aliquots (50 Wl) containing 20 Wl rabbit reticulocyte lysate (Amer-
sham), translation mix (Amersham), 0.1 M potassium acetate, 0.5 mM
magnesium acetate, 60 WCi [35S]methionine (speci¢c activity 1000 Ci/
mmol, Amersham), 4 Wg iNOS mRNA or RAW 264.7 polyA, were
incubated at 30‡C for 90 min. Di¡erent concentrations of PNA (1,
0.1, 0.01 WM of PNA1 and 1 WM PNA2) were simultaneously added
to di¡erent samples at the beginning of incubation. Analysis of trans-
lation products was performed with a 10% SDS-PAGE [25]. After
electrophoresis, the gels were ¢xed with 7% acetic acid for 1 h at
room temperature, then they were dried for 1 h and exposed overnight
to Hyper¢lm L-max autoradiography ¢lm (Amersham).
3. Results
3.1. PNA synthesis
The PNA1 sequence complementary to the 238^251 region
of iNOS cDNA was deliberately chosen to match in proximity
of the beginning of the coding region and in a homopurine
sequence (Section 2.1). The second PNA sequence, used as
control, was obtained by scrambling the bases used for the
¢rst PNA molecule and verifying its non-complementarity to
mouse genomic DNA.
Following their chemical synthesis, both types of PNAs
were puri¢ed as described in [19], with a ¢nal yield of 52%.
The analyses performed as described in Section 2.1 showed a
molecular ion at m/z 3838.23 for both molecules, consistent
with the [M+H] ion of the expected PNAs. The molecular
weights were also con¢rmed by MALDI-TOF spectrometer
analyses (data not shown).
3.2. PNA binding to iNOS mRNA
The radiolabelled iNOS mRNA obtained by SP6 RNA
polymerase transcription was incubated with 1 WM PNA1
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Fig. 1. RNase protection assay demonstrates PNA1 binding to
iNOS mRNA. Lane 1 shows the undigested radiolabelled iNOS
mRNA. Following RNase treatment, an undigested fragment ap-
peared in the PNA1 sample (lane 3), while complete digestion was
observed in the untreated (lane 2) and in the PNA2-treated (lane 4)
samples.
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and 1 WM PNA2 and then digested with RNase (Section 2.4).
Results are shown in Fig. 1. Speci¢cally, lane 1 represents the
undigested radiolabelled iNOS mRNA, lane 2 the same
RNase-digested sample, lane 3, corresponding to the PNA1-
treated sample, shows the presence of a RNase-resistant frag-
ment, and lane 4 represents the PNA2-treated sample in which
absence of non-speci¢c binding is demonstrated by complete
mRNA degradation.
These data indicate that PNA1 binds its complementary
region on iNOS mRNA, thereby preventing RNA digestion,
while a non-speci¢c sequence (PNA2) is unable to inhibit
enzymatic degradation.
3.3. PNA inhibition of iNOS synthesis in the rabbit reticulocyte
lysate system
In order to investigate the selective inhibition of PNA1 on
iNOS translation, two kinds of experiments were performed.
First, iNOS cDNA was transferred into pSP65 plasmid
containing SP6 RNA polymerase promoter and the mRNA
was obtained as in [2,3]. The resulting transcription product
was then incubated in the rabbit reticulocyte lysate system, in
which it generated a 130 kDa protein, corresponding to the
Mr of iNOS (Fig. 2, lane 1). The presence of 1 WM PNA1
cazused the complete disappearance of the 130 kDa protein
(lane 2). Finally, no inhibition whatsoever of iNOS mRNA
translation was apparent in the sample treated with 1 WM
PNA2 (lane 3).
A second approach was designed to check the in£uence of
the speci¢c PNA on protein expression. In these experiments,
a puri¢ed polyA from RAW 264.7 cells was incubated in the
same cell-free translation system, giving rise to a large amount
of products. The puri¢ed mRNA was obtained both from
LPS- and IFNQ-stimulated cells and from untreated ones.
Fig. 3 shows that a 130 kDa protein, consistent with the Mr
of iNOS, was produced only by puri¢ed poly(A) from stimu-
lated RAW 264.7 cells (lane 2), while being undetectable in
the experiments containing poly(A) from unstimulated cells
(lane 1). Previously, the iNOS gene had been found to be
transcribed under the same conditions of stimulation of
RAW 264.7 cells with LPS and IFNQ [22]. Moreover, selective
inhibition of biosynthesis of the 130 kDa protein was a¡orded
in a dose-dependent manner by PNA up to 1 WM (lanes 3^5),
while the highest concentration, i.e. 10 WM PNA1 (lane 6),
resulted in a non-speci¢c inhibition of protein synthesis.
4. Discussion
The combination of bene¢cial [2^4] and detrimental [5^7]
e¡ects a¡orded by a high release of NO by iNOS justi¢es the
need to properly modulate the macrophagic production of
NO. At the same time, it may be critical to avoid any un-
wanted e¡ects on other NO-responsive cells, tissues and or-
gans. Accordingly, recent research has focused on the devel-
opment of selective modulators of iNOS, in order to inhibit
uncontrolled formation of NO without interfering with the
production of NO by endothelial and neuronal isoforms. Con-
ventional inhibitors used so far display their e¡ects on enzyme
functions, so they are substrate analogs, £avoprotein binders
or heme binders, but none of them proved to be devoid of
e¡ects on other NOS isoforms or on other biochemical path-
ways [2]. Inhibitors of induction of this enzyme, such as cor-
ticosteroids, TGF-b, interleukin-4, interleukin-10, and dexa-
methasone, can also interfere with other targets of cellular
metabolism [2,26]. This background suggested the synthesis
of a speci¢c anti-iNOS PNA (PNA1) and the in vitro evalua-
tion of its inhibitory e¡ects on iNOS mRNA translation.
The homopyrimidinic PNA sequence used in these experi-
ments was chosen for its complementarity to the 5P initial
coding region of iNOS and because homopyrimidine PNAs
had been previously demonstrated to form triplexes with com-
plementary dsDNA (DNA2-PNA1) or RNA (RNA1-PNA2)
[27^29]. These properties should allow the PNA to feature
its inhibitory action on the iNOS isoform only.
The RNase protection assay con¢rmed the ability of PNA1
to bind a speci¢c sequence of iNOS mRNA. The inhibitory
e¡ect of PNA1 on iNOS synthesis was then demonstrated
using the rabbit reticulocyte lysate, one of the standard sys-
tems for the study of translation of exogenous mRNA tem-
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Fig. 3. Translation of poly(A) from stimulated and unstimulated
RAW 264.7 cells and inhibition by PNA1. Gel electrophoresis
shows the patterns of proteins obtained by translation of poly(A)
from unstimulated (lane 1) or LPS- and IFNQ-stimulated cells (lanes
2^6). The 130 kDa band (arrow) is present in the case of stimulated
cells only. The presence of 1 WM, 0.1 WM and 0.01 WM PNA1
(lanes 3, 4 and 5, respectively) inhibited expression of iNOS band
without a¡ecting translation of the other proteins. Lane 6 shows the
non-speci¢c inhibitory e¡ect of 10 WM PNA1 on the rabbit reticulo-
cyte lysate system activity.
Fig. 2. PNA1 inhibition of iNOS synthesis in a cell-free translation
system. Full-length iNOS mRNA in the rabbit reticulocyte lysate
system generates a 130 kDa protein corresponding to native iNOS
(lane 1). The presence of 1 WM PNA1 inhibits biosynthesis of iNOS
(lane 2), while 1 WM PNA2 has no e¡ect on the translation (lane
3).
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plates [30]. Translation of the in vitro produced iNOS mRNA
to yield a 130 kDa protein, corresponding to the Mr of iNOS,
was completely inhibited by 1 WM PNA1, while control PNA2
did not a¡ect the system at all (Fig. 2).
A di¡erent approach was followed to test the ability of
PNA1 to exert its speci¢c inhibitory e¡ects in the presence
of a large amount of macrophagic mRNAs. Poly(A) trans-
lation from LPS- and IFNQ-stimulated RAW 264.7 cells was
non-speci¢cally inhibited at 10 WM PNA1 (Fig. 3, lane 6).
Similar data were obtained in a totally di¡erent application
by Gambacorti-Passerini et al. [29] who noticed a non-speci¢c
inhibition of translation at greater than 2 WM PNA in a sim-
ilar cell-free system. In our experiments, a 130 kDa protein
band was apparent in the polyA translation products from
LPS- and IFNQ-stimulated RAW 264.7 cells, which show en-
hanced transcription of iNOS mRNA over unstimulated cells
[22,31,32]. Conversely, the 130 kDa band was not present in
the unstimulated cell sample (Fig. 3), providing further evi-
dence for the identity of this protein with iNOS. Moreover,
synthesis of this protein was selectively inhibited by concen-
trations of PNA1 as low as 0.01 WM.
All these data suggest that PNA1 may be a potentially
useful tool for the pharmacologic control of the high output
NO pathway, although results in intact cells are required to
explore the in vivo applications of this study. Speci¢cally, use
of suitable carriers to transport PNA1 inside cellular compart-
ments, such as hydrophobic peptides, liposomes or red blood
cells [19,33], seems to be the reasonable evolution of this work
and is currently pursued in our laboratory.
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